Table 2 Treatment-related characteristics among age groups*

Operation type

Mastectomy

219 (39)^a

2235 (49.6)^b

378 (57.3)^c

Quadranectomy

342 (61)^a

2270 (50.4)^b

282(42.7)^c

Type of recurrence

Local

6 (7.1)^a

52 (7)^a

9 (6.2)^a

Regional

4 (4.7)^a

11 (1.5)^b

3 (2.1)^b

Distant metastasis

75 (88.2)^a

680 (91.5)^a

133 (91.7)^a

Site of metastasis

Liver

8 (13.3)^a

69 (12.5)^a

10 (11.4)^a

Bone

21 (35)^a

208 (37.5)^a

28 (31.8)^a

Lung

4 (6.7)^a

70 (12.6)^a

29 (33)^b

Brain

8 (13.3)^a

30 (5.4)^b

1 (1.1)^b

Others

8 (13.3)^a

41 (7.4)^a

11 (12.5)^a

Mixed‡

11 (18.3)^b

136 (24.5)^b

9 (10.2)^a

LN management

SLNB

130 (24.1)^a

957 (22.3)^a

104 (18.5)^b

AND

343 (63.6)^a

2885 (67.3)^a

416 (73.9)^b

Both

66 (12.2)^a

443 (10.3)^a

43 (7.6)^b

No. of involved LN

3.93 ± 4.93^a

3.17 ± 3.98^a

2.21 ± 3.35^a

Chemotherapy

Yes

494 (97.4)^a

3640 (97)^a

355 (76.7)^b

No

13 (2.6)^a

111 (3)^a

108 (23.3)^b

Radiotherapy

Yes

416 (89.7)^a

2799 (81.6)^b

247 (58.4)^c

No

48 (10.3)^a

630 (18.4)^b

176 (41.6)^c

Hormone therapy

Yes

327 (73.2)^a

2746 (79)^b

396 (86.1)^c

No

120 (26.8)^a

729 (21)^b

64 (13.9)^c

Type of hormone therapy

Tamoxifen

297 (91.7)^a

1345 (49.5)^b

29 (7.4)^c

Latrazole

15 (4.6)^a

1141 (42)^b

341 (87)^c

Both

11 (3.4)^a

208 (7.7)^b

14 (3.6)^a

Other medications

1 (0.3)^a

24 (0.9)^a

8 (2)^b

Recurrence

≤ 5 yr

42 (16.3)^a

362 (11.7)^b

46 (8.9)^b

> 5 yr

4 (1.6)^a

100 (3.2)^a

19 (3.7)^a

no

211 (82.1)^a

2635 (85.1)^b

452 (87.4)^b